Icelandic pharmaceutical company Alvotech to list on Nasdaq Stockholm

One of Iceland's largest companies, the pharmaceutical firm Alvotech, has announced its intention to list on Nasdaq Stockholm.

Gene therapy restored hearing in children with congenital deafness

Eleven out of twelve children with congenital deafness showed improvements in a study testing Regeneron’s gene therapy for hereditary hearing loss. The U.S. com...

How the Nobel discovery is used in drug development

Regulatory T cells keep the immune system in check, a discovery now awarded the 2025 Nobel Prize in Physiology or Medicine. Qiang Pan Hammarström explains how this finding is being applied in today’s drug development, and what challenges remain....

ZEISS supports the transition of spatial biology to clinical research

Slide scanner ZEISS Axioscan 7 spatial biology provides scalable workflow automation.

Discover Precision: Join ZEISS at the Control Fair in Stuttgart

May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.

ZEN core now available for all ZEISS scanning electron microscopes

Introducing intuitive, streamlined SEM control over imaging, analytics, and multi-modal workflows.

Meet us at Control 2025

Innovations that drive efficiency.

ZEISS receives FDA clearance for INTRABEAM 700

With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.

Samuel Lagercrantz: ”Geoffrey Hintons farhågor”

”Ska vi få en så ljus framtid som möjligt där AI används på bästa sätt behövs både de som ser risker med den nya tekniken och de som ser sig som teknikoptimiste...

Webinar: Can AI replace humans in pharmacovigilance?

The webinar will explore how AI can transform pharmacovigilance by enhancing efficiency, reducing errors, and addressing challenges such as software costs, data...

Alvotech flyttar in i svenskt life sciene-kluster

Isländska Alvotech, noterade på Stockholmsbörsen, flyttar in på Campus Solna. ”Alvotech strävar efter att avsevärt expandera sin forsknings- och utvecklingsverk...

ZEISS EVO as the Key to Wire Technology in Modern Medicine

High-performance wires for stents.

Vaccine project targeting congenital infection scrapped in late-stage trial – “Clearly disappointed”

Hope for the first vaccine against the world’s most common congenital infection has taken a serious hit

New ATMP center inaugurated: “In the future, we will see cell and gene therapies in all clinics”

Karolinska Institutet and Karolinska University Hospital’s new ATMP center was inaugurated in Flemingsberg, south of Stockholm. “The ATMP Center is not just a p...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2025)

ZEISS introduces the new Smartzoom 100

The future of digital microscopy for efficient optical inspections.

Astra Zeneca pauses multi-million investment in the UK

Astra Zeneca has paused a planned investment worth $270 million. It is the latest pharmaceutical company to pull back on its commitments in the UK.

Health politician Lina Nordquist: ”I find it hard to be idle”

She is the pharmacist and researcher who grew tired of the breakthroughs that never materialised and knowledge that never seemed to reach patients, so she decid...

ZEISS Quality Innovations at CONTROL

May 6-9, 2025 in Stuttgart.

Thermo Fisher-team flyttar in hos Astra Zeneca Bioventurehub – inleder samarbete

Amerikanska Thermo Fisher och Astra Zeneca Bioventurehub krokar arm i ett nytt FoU-partnerskap. Bolagen ska samlokalisera i Goco Health Innovation City, Göteborg.

Astra Zeneca avslutar tillverkning i Indien – lämnar in licensen

Astra Zeneca skyndar på planerna att avsluta sin produktion i Indien. Företaget avsäger sig nu sin tillverkningslicens i landet två år innan den skulle ha löpt ut.

Cost-efficient development of laboratory devices

8 ways to optimise development costs and speed up processes

The top five most expensive drugs in 2025

New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...

Södertäljebolag tar in 440 miljoner inför klinisk cancerstudie

Cellterapibolaget Anocca har lyckats ta in närmare 440 miljoner kronor i en ny finansieringsrunda för att stödja kommande kliniska prövningar inom bukspottkörtelcancer.